fbpx

Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting

Silk
Road Medical, Inc., a company dedicated to preventing the
devastating burden of stroke through surgical innovation, today
announced key events at the upcoming Society for Vascular Surgery 2018
Vascular Annual Meeting (VAM) June 20-23 at the Hynes Convention Center
in Boston. These include real-world data presentations comparing the
company’s TransCarotid Artery Revascularization (TCAR) procedure to
transfemoral carotid artery stenting (TFCAS) and carotid endarterectomy
(CEA), as well as other company-sponsored events about TCAR.

Two podium presentations will feature data from the Society for Vascular
Surgery’s TCAR
Surveillance Project, launched in 2016 to obtain real-world
comparative outcomes of TCAR and other carotid artery treatments from
centers participating in the Vascular Quality Initiative (VQI):

Silk Road Medical will be hosting TCAR @ Vascular Live on June 21 from
3-3:30 p.m. in the Exhibit Hall. “TCAR: Latest Stroke Prevention Data
Signals Standard of Care Potential in Carotid Revascularization” will
be presented by Dr. Marc Schermerhorn, Dr. Jeffrey Jim of University of
Washington School of Medicine (St. Louis), Dr. Peter Schneider of Kaiser
Permanente Medical Center (Honolulu) and Dr. Sumaira Macdonald of Silk
Road Medical.

TCAR will also be featured in the interactive poster sessions:

Silk Road Medical will be exhibiting in booth #806.

About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent
System

TCAR (TransCarotid Artery Revascularization) is a clinically proven
procedure combining surgical principles of neuroprotection with
minimally invasive endovascular techniques to treat blockages in the
carotid artery at risk of causing a stroke. The ENROUTE Transcarotid
Stent is intended to be used in conjunction with the ENROUTE
Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The
ENROUTE Transcarotid NPS is a first in class device used to directly
access the common carotid artery and initiate high rate temporary blood
flow reversal to protect the brain from stroke while delivering and
implanting the ENROUTE Transcarotid Stent.

About Silk Road Medical

Silk Road Medical, Inc. is a private company located in Sunnyvale,
California, that develops and manufactures less-invasive medical devices
intended to improve the treatment of vascular disease through
proprietary transcarotid therapies. The company’s TCAR procedure
addresses the concerns of millions of people with carotid artery disease
who are at an increased risk of stroke. Detailed information can be
found at www.silkroadmed.com.

ENROUTE is a registered trademark of Silk Road Medical, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005276/en/